Fig. 3: Therapeutic strategies of stroma re-engineering.
From: Cancer-associated fibroblasts: from basic science to anticancer therapy
Current strategies to selectively target tumor-promoting CAFs include (a) blocking the differentiation from precursor cells to tumor-promoting CAFs via inhibition of precursor activation or targeting key signaling pathways in differentiation. b Targeted depletion of tumor-promoting CAFs without affecting tumor-restraining CAFs through genetic manipulation or specific antibodies. c Induction of phenotypic switching from tumor-promoting to tumor-restraining CAFs. d Targeting the crosstalk between cancer cells and tumor-promoting CAFs to inhibit their supportive effect on cancer proliferation, migration and chemoresistance.
